3-cyano-N,N-diethyl-4-(4-(3-fluoroprop-1-yn-1-yl)phenyl)-4-oxobutanamide | 1580494-65-0

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 3-cyano-N,N-diethyl-4-(4-(3-fluoroprop-1-yn-1-yl)phenyl)-4-oxobutanamide
• CAS: 1580494-65-0
• 化学式: C₁₈H₁₉FN₂O₂
• 分子量: 314.359
• InChiKey: XDQUOTVWMWVQLM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.59
• 重原子数：
  23.0
• 可旋转键数：
  6.0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.39
• 拓扑面积：
  61.17
• 氢给体数：
  0.0
• 氢受体数：
  3.0

反应信息

• 作为反应物：
  描述：

  3-cyano-N,N-diethyl-4-(4-(3-fluoroprop-1-yn-1-yl)phenyl)-4-oxobutanamide 在 一水合肼 、 溶剂黄146 作用下， 以 乙醇 为溶剂， 反应 13.0h， 生成 N,N-diethyl-2-(2-(4-(3-fluoroprop-1-yn-1-yl)phenyl)-5,7-dimethylpyrazolo[1,5-a]pyrimidin-3-yl)acetamide
  参考文献：
  名称：

  Preparation and evaluation of novel pyrazolo[1,5-a]pyrimidine acetamides, closely related to DPA-714, as potent ligands for imaging the TSPO 18kDa with PET

  摘要：

  A series of four novel analogues of DPA-714, bearing a fluoroalkynyl side chain (with a length ranging from three to six carbon atoms) in replacement of the fluoroethoxy motif, have been synthetized in six steps from commercially available methyl 4-iodobenzoate. The synthetic strategy for the preparation of these N,N-diethyl-2-(2-(4-(omega-fluoroalk-1-ynyl) phenyl)-5,7-dimethylpyrazolo[1,5-a] pyrimidin-3-yl) acetamides (7a-d) consisted in derivatizing a key iodinated building block featuring the pyrazolopyrimidine acetamide backbone of DPA-714, by Sonogashira couplings with various alkynyl reagents. The resulting alkynols were subsequently fluorinated, yielding the expected target derivatives. All four analogues exhibited slightly higher affinity and selectivity towards the TSPO 18 kDa (K-i vs [H-3]PK11195: 0.35-0.79 nM; Ki vs [H-3] flunitrazepam: > 1000 nM) when compared to DPA-714 (Ki vs [H-3] PK11195: 0.91 nM; Ki vs [H-3] flunitrazepam: > 1000 nM). Lipophilicities (HPLC, logD(7.4)) increased with the chain length (from 3.6 to 4.3) and were significantly higher than the one determined for DPA-714 (2.9). Preliminary in vitro metabolism evaluation using rat microsomal incubations and LC-MS analyses showed, for all four novel analogues, the absence of defluorinated metabolites. Among them, the fluoropentynyl compound, DPA-C5yne (7c), was selected, labelled in one single step with fluorine-18 from the corresponding tosylate and in vivo evaluated with PET on our in-house-developed rat model of acute local neuroinflammation. (C) 2014 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2014.01.080
• 作为产物：
  描述：

  4-(3-羟基-1-丙炔)苯甲酸甲酯 在 正丁基锂 、 sodium hydroxide 、 [双(2-甲氧基乙基)胺]三氟化硫 作用下， 以 四氢呋喃 、 乙醇 、 二氯甲烷 为溶剂， 反应 146.75h， 生成 3-cyano-N,N-diethyl-4-(4-(3-fluoroprop-1-yn-1-yl)phenyl)-4-oxobutanamide
  参考文献：
  名称：

  Preparation and evaluation of novel pyrazolo[1,5-a]pyrimidine acetamides, closely related to DPA-714, as potent ligands for imaging the TSPO 18kDa with PET

  摘要：

  A series of four novel analogues of DPA-714, bearing a fluoroalkynyl side chain (with a length ranging from three to six carbon atoms) in replacement of the fluoroethoxy motif, have been synthetized in six steps from commercially available methyl 4-iodobenzoate. The synthetic strategy for the preparation of these N,N-diethyl-2-(2-(4-(omega-fluoroalk-1-ynyl) phenyl)-5,7-dimethylpyrazolo[1,5-a] pyrimidin-3-yl) acetamides (7a-d) consisted in derivatizing a key iodinated building block featuring the pyrazolopyrimidine acetamide backbone of DPA-714, by Sonogashira couplings with various alkynyl reagents. The resulting alkynols were subsequently fluorinated, yielding the expected target derivatives. All four analogues exhibited slightly higher affinity and selectivity towards the TSPO 18 kDa (K-i vs [H-3]PK11195: 0.35-0.79 nM; Ki vs [H-3] flunitrazepam: > 1000 nM) when compared to DPA-714 (Ki vs [H-3] PK11195: 0.91 nM; Ki vs [H-3] flunitrazepam: > 1000 nM). Lipophilicities (HPLC, logD(7.4)) increased with the chain length (from 3.6 to 4.3) and were significantly higher than the one determined for DPA-714 (2.9). Preliminary in vitro metabolism evaluation using rat microsomal incubations and LC-MS analyses showed, for all four novel analogues, the absence of defluorinated metabolites. Among them, the fluoropentynyl compound, DPA-C5yne (7c), was selected, labelled in one single step with fluorine-18 from the corresponding tosylate and in vivo evaluated with PET on our in-house-developed rat model of acute local neuroinflammation. (C) 2014 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2014.01.080